Stock analysts at Jefferies Group boosted their price objective on shares of Cubist Pharmaceuticals (NASDAQ:CBST) to $70.00 in a report issued on Wednesday, Analyst Ratings Network reports. Jefferies Group’s target price would indicate a potential upside of 12.31% from the stock’s previous close.
Shares of Cubist Pharmaceuticals (NASDAQ:CBST) traded up 3.21% during mid-day trading on Wednesday, hitting $64.33. Cubist Pharmaceuticals has a 52 week low of $38.53 and a 52 week high of $64.70. The stock’s 50-day moving average is currently $52.68. The company has a market cap of $4.247 billion and a P/E ratio of 43.02.
Cubist Pharmaceuticals (NASDAQ:CBST) last posted its quarterly earnings results on Thursday, July 18th. The company reported $0.42 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.55 by $0.13. The company had revenue of $258.80 million for the quarter, compared to the consensus estimate of $254.93 million. During the same quarter last year, the company posted $0.68 earnings per share. Cubist Pharmaceuticals’s revenue was up 12.2% compared to the same quarter last year. Analysts expect that Cubist Pharmaceuticals will post $1.07 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on CBST. Analysts at Cantor Fitzgerald reiterated a “hold” rating on shares of Cubist Pharmaceuticals in a research note to investors on Wednesday. They now have a $65.00 price target on the stock, up previously from $50.00. Separately, analysts at UBS AG raised their price target on shares of Cubist Pharmaceuticals from $61.00 to $70.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Credit Suisse upgraded shares of Cubist Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday. They now have a $69.00 price target on the stock, up previously from $56.00.
Seven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $61.08.
In other Cubist Pharmaceuticals news, Director Nancy J. Hutson sold 5,000 shares of the company’s stock in a transaction that occured on Friday, July 26th. The shares were sold at an average price of $53.87, for a total value of $269,350.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.